New TIG­IT da­ta cut from Gilead, Ar­cus sets the stage for full read­out

Gilead and Ar­cus are once again de­clar­ing suc­cess for their TIG­IT ther­a­py with­out spelling out the da­ta — al­though this time, they promise the num­bers are just around the cor­ner.

Tout­ing pos­i­tive re­sults from the fourth in­ter­im analy­sis of ARC-7, the part­ners said the open-la­bel Phase II tri­al con­tin­ues to show “mean­ing­ful dif­fer­en­ti­a­tion” for first-line non-small cell lung can­cer pa­tients tak­ing the an­ti-TIG­IT drug dom­vanal­imab. They added that the full re­sults — over­all re­sponse rate, pro­gres­sion-free sur­vival, dis­ease con­trol rate and all — will be pre­sent­ed in the com­ing weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER